Anti-tumor activity of FF-10850 (liposomal topotecan) in patients with advanced Merkel cell carcinoma.
Journal of Clinical Oncology · 2026-05-28
Zelenectide pevedotin (BT8009) monotherapy in previously treated metastatic urothelial carcinoma (mUC): Update on Duravelo-1.
Journal of Clinical Oncology · 2026-05-27
First data disclosure from the first-in-human phase 1/2 trial of SMP-3124LP, the first investigational pegylated liposome CHK1 inhibitor, in patients with selected advanced solid tumors.
Journal of Clinical Oncology · 2026-05-27
EIK1003, a PARP1-selective inhibitor, in combination with paclitaxel (PTX): Initial combination and updated monotherapy results from a phase 1/2 study EIK1003-001 in advanced solid tumors.
Journal of Clinical Oncology · 2026-05-27
Overall survival analysis of a heavily pretreated population of patients with bone sarcomas treated with mecbotamab vedotin, a conditionally binding ADC targeting AXL.
Journal of Clinical Oncology · 2026-05-27
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer
British Journal of Cancer · 2026-04-03
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
The Lancet Oncology · 2026-03-31 · 1 citations
Phase I Trial of P-PSMA-101 CAR T Cells in Patients with Metastatic Castration-Resistant Prostate Cancer
Clinical Cancer Research · 2026-03-04
Nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients with metastatic castration-resistant prostate cancer (mCRPC) or metastatic clear cell renal cell carcinoma (mccRCC): A phase 1/2 study.
Journal of Clinical Oncology · 2026-03-01
A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors
npj Precision Oncology · 2026-02-28 · 2 citations
Bayesian modeling allows early inference of pharmacokinetic/pharmacodynamic relationship for a novel small molecule STING agonist in Phase I
2026-01-01
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation
Journal of Clinical Oncology · 2025-11-06 · 5 citations
615 Phase 1 study of intratumoral VAX014 with dose expansion in combination with pembrolizumab or nivolumab in patients with advanced solid tumors
Regular and Young Investigator Award Abstracts · 2025-11-01
523 Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC
Regular and Young Investigator Award Abstracts · 2025-11-01
561 A Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TNG260 in combination with pembrolizumab in patients with STK11-mutated advanced solid tumors
Regular and Young Investigator Award Abstracts · 2025-11-01
Abstract C070: Evolving Paradigms and shifting priorities in the landscape of Phase 1 Oncology Trials: 2021–2024
Molecular Cancer Therapeutics · 2025-10-22
Supplemental Table 3 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 ImmunotherapyPreprint
2025-10-15
Supplemental Table 1 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 ImmunotherapyPreprint
2025-10-15
Supplemental Figure 5 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 ImmunotherapyPreprint
2025-10-15
Supplemental Figure 4 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 ImmunotherapyPreprint
2025-10-15